17-19 The CAROLINA and CARMELINA studies of linagliptin demonstrated CV safety, but results have not yet been made available (Clinicaltrials.gov identifiers: NCT01243424 and NCT01897532)
Napolitano, A., Memoli, S., Crescenzi, O
References Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al
This is where formulation science becomes critical
Among these are drugs that have already received clinical approval and have been extensively utilized in other fields
Relative expression levels were determined by real-time PCR on a Bio-Rad CFX Connect or Real-Time System (CFX96 Real-Time System) using SYBR Green or the PowerUp SYBR Green kit (Thermo Fisher Scientific), and the primer sequences are listed in Supplemental Methods